Antonio Augusto Lopes

List of Publications by Year
in descending order

83 papers	1,620 citations	304743 22 h-index	315739 38 g-index
88 all docs	88 docs citations	88 times ranked	1927 citing authors

#	Article	IF	Citations
1	Postoperative Pulmonary Hemodynamics and Systemic Inflammatory Response in Pediatric Patients Undergoing Surgery for Congenital Heart Defects. Mediators of Inflammation, 2022, 2022, 1-12.	3.0	3
2	Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: Relation to hemodynamic parameters and the presence of Down syndrome. Cytokine, 2020, 134, 155192.	3.2	1
3	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulmonary Circulation, 2019, 9, 1-9.	1.7	7
4	Relation of Macrophage Migration Inhibitory Factor to Pulmonary Hemodynamics and Vascular Structure and Carbamyl-Phosphate Synthetase I Genetic Variations in Pediatric Patients with Congenital Cardiac Shunts. Mediators of Inflammation, 2019, 2019, 1-10.	3.0	6
5	Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments. Pulmonary Circulation, 2019, 9, 1-13.	1.7	9
6	Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. Congenital Heart Disease, 2019, 14, 246-255.	0.2	7
7	Morphologic and immunohistochemical features of pulmonary vasculopathy in end-stage left ventricular systolic failure. Journal of Heart and Lung Transplantation, 2018, 37, 422-425.	0.6	3
8	Endothelial Alterations in Pulmonary Hypertension. , 2018, , 439-451.		1
9	Factors influencing outcomes in patients with Eisenmenger syndrome: a nineâ€year followâ€up study. Pulmonary Circulation, 2017, 7, 635-642.	1.7	6
10	Relation of Cytokine Profile to Clinical and Hemodynamic Features in Young Patients With Congenital Heart Disease and Pulmonary Hypertension. American Journal of Cardiology, 2017, 119, 119-125.	1.6	11
11	When to Operate on Pediatric Patients with Congenital Heart Disease and Pulmonary Hypertension. Arquivos Brasileiros De Cardiologia, 2017, 109, 183-184.	0.8	1
12	Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	5
13	Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension. Thrombosis Research, 2016, 146, 15-19.	1.7	6
14	Cardiac Catheterization in Children with Pulmonary Hypertensive Vascular Disease: Consensus Statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. Pulmonary Circulation, 2016, 6, 118-125.	1.7	49
15	Abstract 10210: Effects of Chronic Treatment With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil on Platelet Aggregation in Patients With Eisenmenger Syndrome. Circulation, 2015, 132, .	1.6	0
16	Capillary hemangiomatosis likeâ€lesions in lung biopsies from children with congenital heart defects. Pediatric Pulmonology, 2014, 49, E82-5.	2.0	8
17	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Annals of Thoracic Medicine, 2014, 9, 1.	1.8	11
18	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease. Annals of Thoracic Medicine, 2014, 9, 21.	1.8	13

#	Article	IF	Citations
19	Congenital Heart Disease and Pulmonary Arterial Hypertension in South America (2013 Grover) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	2
20	Repair of Congenital Heart Disease with Associated Pulmonary Hypertension in Children: What are the Minimal Investigative Procedures? Consensus Statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2014, 4, 330-341.	1.7	44
21	Atrial Septal Defect in Adults: Does Repair Always Mean Cure?. Arquivos Brasileiros De Cardiologia, 2014, 103, 446-8.	0.8	7
22	Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease. Brazilian Journal of Medical and Biological Research, 2013, 46, 375-381.	1.5	6
23	Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease. Clinics, 2013, 68, 531-536.	1.5	7
24	Is Surgical Treatment the Cure for Patients with Congenital Heart Disease?. Pulmonary Circulation, 2012, 2, 273-274.	1.7	3
25	AusÃªncia de estreita associaÃ§Ã£o entre qualidade de vida e capacidade de exercÃcio na hipertensÃ£o arterial pulmonar. Arquivos Brasileiros De Cardiologia, 2012, 99, 876-885.	0.8	8
26	Myocarditis in children and detection of viruses in myocardial tissue: Implications for immunosuppressive therapy. International Journal of Cardiology, 2011, 148, 204-208.	1.7	34
27	Tratamento cirÃºrgico da persistÃªncia do canal arterial na populaÃ§Ã£o adulta. Brazilian Journal of Cardiovascular Surgery, 2011, 26, 93-97.	0.6	6
28	HipertensÃ£o arterial pulmonar hereditÃ¡ria apresentando-se como venopatia oclusiva. Arquivos Brasileiros De Cardiologia, 2011, 97, e8-e10.	0.8	1
29	Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. Brazilian Journal of Medical and Biological Research, 2011, 44, 1269-1275.	1.5	23
30	Functional Classification of Pulmonary Hypertension in Children: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 280-285.	1.7	92
31	A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 286-298.	1.7	215
32	Pulmonary Hypertension Secondary to Congenital Systemic-to-Pulmonary (Left-to-Right) Shunts. , 2011, , 1139-1151.		0
33	Pulmonary Hypertension in Latin America. Chest, 2010, 137, 78S-84S.	0.8	23
34	NKX2.5 mutations in patients with non-syndromic congenital heart disease. International Journal of Cardiology, 2010, 138, 261-265.	1.7	53
35	Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thrombosis Research, 2010, 125, 38-43.	1.7	30
36	The Impact of Preexisting Myocardial Remodeling onÂVentricular Function Early after Tetralogy of Fallot Repair. Journal of the American Society of Echocardiography, 2010, 23, 912-918.	2.8	21

#	Article	IF	Citations
37	Sleep in Infants with Congenital Heart Disease. Clinics, 2009, 64, 1205-1210.	1.5	24
38	Resultados do tratamento cirÃºrgico da coarctaÃ§Ã£o de aorta em adultos. Brazilian Journal of Cardiovascular Surgery, 2009, 24, 346-353.	0.6	10
39	Causes of death and cardiovascular complications in adolescents and adults with congenitally malformed hearts: an autopsy study of 102 cases. Cardiology in the Young, 2009, 19, 511-516.	0.8	3
40	Can we start to think about consensus-oriented clinical practices?. Cardiology in the Young, 2009, 19, 1-3.	0.8	9
41	A computer-based matrix for rapid calculation of pulmonary hemodynamic parameters in congenital heart disease. Annals of Thoracic Medicine, 2009, 4, 124.	1.8	3
42	Measurement, interpretation and use of hemodynamic parameters. Cardiology in the Young, 2009, 19, 8-12.	0.8	22
43	Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiology in the Young, 2009, 19, 431-435.	0.8	53
44	Age and Method-dependent Variability of Predicted Oxygen Consumption in Congenital Heart Disease. Congenital Heart Disease, 2009, 4, 96-102.	0.2	0
45	ALDH1A2 (RALDH2) genetic variation in human congenital heart disease. BMC Medical Genetics, 2009, 10, 113.	2.1	38
46	Frequency of 22q11.2 microdeletion in sporadic non-syndromic tetralogy of Fallot cases. International Journal of Cardiology, 2008, 126, 374-378.	1.7	22
47	Altered endothelial function following the Fontan procedure. Cardiology in the Young, 2008, 18, 70-4.	0.8	76
48	PrevalÃªncia e abordagem cirÃºrgica da estenose supravalvar pulmonar pÃ³s-operaÃ§Ã£o de jatene para transposiÃ§Ã£o das grandes artÃ©rias. Arquivos Brasileiros De Cardiologia, 2008, 91, 18-24.	0.8	14
49	PCR screening for 22q11.2 microdeletion: Development of a new cost-effective diagnostic tool. Clinica Chimica Acta, 2006, 369, 78-81.	1.1	10
50	Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2006, 4, 53-59.	1.0	8
51	Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 175-183.	1.7	8
52	Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation. Cardiology in the Young, 2005, 15, 26-30.	0.8	28
53	Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome. Cardiology in the Young, 2005, 15, 504-513.	0.8	11
54	Increased Tyrosine Phosphorylation of Platelet Proteins Including pp125FAK Suggests Endogenous Activation and Aggregation in Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 411-415.	1.7	8

#	Article	IF	Citations
55	Lack of evidence of association between MTHFR C677T polymorphism and congenital heart disease in a TDT study design. International Journal of Cardiology, 2005, 105, 15-18.	1.7	21
56	Doppler flow evaluation can anticipate abnormal left lung perfusion after transcatheter closure of patent ductus arteriosus. European Heart Journal, 2004, 25, 1927-1933.	2.2	7
57	Age-Dependent Likelihood of In Situ Thrombosis in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 217-223.	1.7	18
58	Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. American Journal of Medicine, 2004, 116, 369-374.	1.5	120
59	Morphology of the Internal Elastic Lamina in Arteries from Pulmonary Hypertensive Patients: a Confocal Laser Microscopy Study. Modern Pathology, 2003, 16, 411-416.	5.5	28
60	Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 251-258.	1.7	12
61	Circulating blood volumes in pulmonary hypertension associated with erythrocytosis â€“ the effects of therapeutic hemodilution. Cardiology in the Young, 2003, 13, 544-550.	0.8	4
62	2566 Likelihood of left main coronary artery compression in pulmonary hypertension based on the diameter of the pulmonary trunk. European Heart Journal, 2003, 24, 482.	2.2	0
63	P3381 Age-dependent risk of in situ thrombosis in secondary pulmonary hypertension. European Heart Journal, 2003, 24, 649.	2.2	0
64	P1152 Evaluation of pulmonary flow by Doppler echocardiography and scintigraphy after percutaneous closure of patent ductus arteriosus. European Heart Journal, 2003, 24, 213.	2.2	0
65	Endothelial Dysfunction Associated with Chronic Intravascular Coagulation in Secondary Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 353-358.	1.7	28
66	A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography. Brazilian Journal of Medical and Biological Research, 2002, 35, 1259-1263.	1.5	8
67	Differential Effects of Enzymatic Treatments on the Storage and Secretion of von Willebrand Factor by Human Endothelial Cells. Thrombosis Research, 2001, 101, 291-297.	1.7	24
68	Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. American Heart Journal, 2000, 139, 618-623.	2.7	43
69	Two Novel Antiâ€“von Willebrand Factor Monoclonal Antibodies. Thrombosis Research, 2000, 97, 3-13.	1.7	9
70	Orally Administered Acetylsalicylic Acid Decreases Protein Incorporation into the Cytoskeleton of Thrombin-Stimulated Platelets. Thrombosis Research, 1999, 95, 335-339.	1.7	0
71	Sialic acid content of von Willebrand factor subunit. Clinica Chimica Acta, 1998, 273, 209-211.	1.1	2
72	Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. American Journal of Medicine, 1998, 105, 21-26.	1.5	41

#	Article	IF	Citations
73	Stimulation of Human Smooth Muscle Cell Proliferation by Thrombin Involves Increased Synthesis of Platelet-Derived Growth Factor. Chest, 1998, 114, 236-240.	0.8	10
74	Circulating von Willebrand Factor Antigen as a Predictor of Short-term Prognosis in Pulmonary Hypertension. Chest, 1998, 114, 1276-1282.	0.8	66
75	An immunohistochemical study of arterial lesions due to pulmonary hypertension in patients with congenital heart defects. Cardiology in the Young, 1994, 4, 37-43.	0.8	3
76	Circulating Platelet Aggregates Indicative of in Vivo Platelet Activation in Pulmonary Hypertension. Angiology, 1993, 44, 701-706.	1.8	32
77	Abnormal Multimeric and Oligomeric Composition Is Associated With Enhanced Endothelial Expression of von Willebrand Factor in Pulmonary Hypertension. Chest, 1993, 104, 1455-1460.	0.8	34
78	A Rapid Method for the Detection of Alpha^{Iâ€™6}⁵ Hereditary Elliptocytosis. Acta Haematologica, 1993, 89, 52-53.	1.4	0
79	Proteins C and S in Two Different Vaso-Occlusive Disorders. Acta Haematologica, 1993, 89, 54-55.	1.4	1
80	Von Willebrand factor in severe pulmonary vascular obstructive disease â€" A structural and functional study in patients with schistosomiasis. Journal of Molecular and Cellular Cardiology, 1992, 24, 174.	1.9	1
81	Lung Î²-Adrenoceptors in Pulmonary Hypertension*. Chest, 1991, 99, 637-641.	0.8	6
82	Aggregation of platelets in whole blood from children with pulmonary hypertension. International Journal of Cardiology, 1990, 28, 173-178.	1.7	6
83	Effect of Intentional Hemodilution on Platelet Survival in Secondary Pulmonary Hypertension. Chest, 1989, 95, 1207-1210.	0.8	19